These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 26327240)

  • 41. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
    Emma MR; Iovanna JL; Bachvarov D; Puleio R; Loria GR; Augello G; Candido S; Libra M; Gulino A; Cancila V; McCubrey JA; Montalto G; Cervello M
    Cell Death Dis; 2016 Jun; 7(6):e2269. PubMed ID: 27336713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
    Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
    Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.
    Kim JB; Lee M; Park SY; Lee S; Kim HR; Lee HS; Yoon JH; Kim YJ
    Mol Med Rep; 2015 Dec; 12(6):8247-52. PubMed ID: 26460271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z; Yuan X; Qu Y; Li X; Wu G; Li C; Zu X; Yang N; Ke X; Zhou J; Xie N; Xu X; Liu S; Shen Y; Li H; Zhang W
    Cancer Lett; 2017 Sep; 403():195-205. PubMed ID: 28645563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
    Houessinon A; François C; Sauzay C; Louandre C; Mongelard G; Godin C; Bodeau S; Takahashi S; Saidak Z; Gutierrez L; Régimbeau JM; Barget N; Barbare JC; Ganne N; Chauffert B; Coriat R; Galmiche A
    Mol Cancer; 2016 May; 15(1):38. PubMed ID: 27184800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
    Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
    Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
    Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
    Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
    Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG
    Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
    Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
    Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
    Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
    Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma.
    Zhang X; Hua L; Yan D; Zhao F; Liu J; Zhou H; Liu J; Wu M; Zhang C; Chen Y; Chen B; Hu B
    Oncol Rep; 2016 Dec; 36(6):3456-3464. PubMed ID: 27748915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells.
    Yin W; Xiang D; Wang T; Zhang Y; Pham CV; Zhou S; Jiang G; Hou Y; Zhu Y; Han Y; Qiao L; Tran PH; Duan W
    Sci Rep; 2021 May; 11(1):10791. PubMed ID: 34031441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
    Liang Y; Chen J; Yu Q; Ji T; Zhang B; Xu J; Dai Y; Xie Y; Lin H; Liang X; Cai X
    Cancer Med; 2017 Dec; 6(12):2787-2795. PubMed ID: 29030911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
    Jin W; Chen L; Cai X; Zhang Y; Zhang J; Ma D; Cai X; Fu T; Yu Z; Yu F; Chen G
    Oncol Rep; 2017 Jan; 37(1):273-280. PubMed ID: 27878301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
    Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
    Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.